Fenretinide Metabolism in Humans and Mice: Utilizing Pharmacologic Modulation of its Metabolic Pathway to Increase Systemic Exposure

Jason P. Cooper¹, Kyunghwa Hwang¹, Hardeep Singh¹, Dong Wang¹, C. Patrick Reynolds¹-⁴, Robert W. Curley Jr.⁵, Simon C Williams¹, Barry J. Maurer¹,³,⁴, and Min H. Kang¹-³

Cancer Center and Departments of ¹Cell Biology & Biochemistry, ²Pharmacology & Neuroscience, ³Internal Medicine and ⁴Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX; ⁵Division of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH

Running title: Increasing Fenretinide Levels by Ketoconazole

Notes: JPC and KH equally contributed to the work.

Key words: fenretinide, metabolism, ketoconazole, pediatric cancers

Correspondence: Min H. Kang, PharmD
School of Medicine, Texas Tech University Health Sciences Center
3601 4th Street, Mail Stop 6540
Lubbock, TX, 79430
Phone: 806-743-2694
Fax: 806-743-2990
E-mail: min.kang@ttuhsc.edu
SUMMARY

BACKGROUND AND PURPOSE
High plasma levels of 4-HPR (fenretinide; N-(4-hydroxyphenyl)retinamide) were associated with improved outcome in a phase II clinical trial. Low bioavailability of 4-HPR has been limiting its therapeutic applications. The study aims to characterize 4-HPR (fenretinide; N-(4-hydroxyphenyl)retinamide) metabolism in humans and mice, and to explore ketoconazole, an inhibitor of CYP3A4, as a modulator to increase 4-HPR plasma levels in mice to overcome the low bioavailability of 4-HPR.

EXPERIMENTAL APPROACH
4-HPR metabolites were identified by mass spectrometric analysis and levels of 4-HPR and its metabolites (4-MPR and 4-oxo-4-HPR) were quantified by HPLC. Kinetic analysis of enzyme activities and the effects of enzyme inhibitors were performed in pooled human and pooled mouse liver microsomes, and in human CYP3A4 isoenzyme microsomes. In vivo inhibition of metabolism was conducted in mice.

KEY RESULTS
Six 4-HPR metabolites were identified in the plasma of patients and mice. 4-HPR was oxidized to 4-oxo-4-HPR, at least in part via human CYP3A4. The CYP3A4 inhibitor ketoconazole significantly reduced 4-oxo-4-HPR formation in both human and mouse liver microsomes. In two strains of mice, co-administration of ketoconazole with 4-HPR significantly increased 4-HPR plasma concentrations by > 2-fold over 4-HPR alone.

CONCLUSIONS AND IMPLICATIONS
Mice may serve as an in vivo model of human 4-HPR pharmacokinetics and in vivo data suggest that the co-administration of ketoconazole at normal treatment doses with 4-HPR may increase systemic 4-HPR concentrations in humans.
Abbreviations

4-EPR, N-(4-ethoxyphenyl)retinamide; 4-HPR, fenretinide or N-(4-hydroxyphenyl)retinamide; 4-MPR, N-(4-methoxyphenyl)retinamide; 4-oxo-4-HPR, 4-oxo-N-(4-hydroxyphenyl)retinamide; CYP, cytochrome P450; HLM, human liver microsomes; LC/MS/MS, liquid chromatography-tandem mass spectrometry; MLM, mouse liver microsomes; NOD/SCID, non-obese diabetic/severe combined immune deficiency; RT-PCR, real-time reverse transcription-polymerase chain reaction.
INTRODUCTION

Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) is a synthetic analog of all-trans retinoic acid (ATRA) that exhibits cytotoxic activity against a variety of human cancer cell lines in vitro at concentrations of 1 – 10 µM (Delia et al., 1993; Kalemkerian et al., 1995; Mariotti et al., 1994; O'Donnell et al., 2002; Oridate et al., 1996). 4-HPR has also been studied clinically both as a chemopreventative agent in breast (Veronesi et al., 1999), bladder (Sabichi et al., 2008), and oral mucosal cancers (Chiesa et al., 2005), and more recently as a chemotherapeutic agent in pediatric (Garaventa et al., 2003; Villablanca et al., 2006) and adult cancers (Puduvalli et al., 2004; Reynolds et al., 2007; Vaishampayan et al., 2005). Despite substantial in vitro cytotoxicity, response rates in clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the oral capsule formulation employed (Cheng et al., 2001; Puduvalli et al., 2004; Reynolds et al., 2007; Vaishampayan et al., 2005; William, Jr. et al., 2009).

After a single 10 mg·kg\(^{-1}\) dose of the capsules, the oral bioavailability of 4-HPR was approximately 16% in beagle dogs (Liu et al., 2007). In chemoprevention studies utilizing chronic, low-dose schedules (100-400 mg daily), 4-HPR plasma concentrations were ≤ 3 µM (Formelli and Cleris, 1993). A pediatric phase I study in neuroblastoma patients achieved a mean 4-HPR plasma level of 9.9 µM at the maximum tolerated dose, 2450 mg·m\(^{-2}\) per day (Villablanca et al., 2006). While in adults, high dose schedules (1800 mg·m\(^{-2}\) per day) have achieved 4-HPR plasma concentrations of 5 to 7 µM with wide interpatient variation (Garcia et al., 2004; Jasti et al., 2001). Pharmacokinetic data in both children and adults have suggested that gastrointestinal absorption was limited at higher doses during phase I studies. New oral and intravenous formulations of 4-HPR have been developed to improve bioavailability of the drug (Liu et al., 2007; Maurer et al., 2007), and are currently being tested in phase I trials in pediatric and adult malignancies (Marachelian et al., 2009; Mohrbacher et al., 2007).
interim results from these trials suggest that increased clinical activity accompanies increased systemic exposures. Complete responses were observed in 4 of 18 neuroblastoma patients at the highest five dosing levels tested with an improved oral powder formulation (4-HPR/Lym-X-Sorb(108,684),(539,709)™ oral powder) (Marachelian et al., 2009), and a 50% response rate (partial + complete) in 10 patients with relapsed T-cell lymphomas was observed using a novel intravenous emulsion 4-HPR formulation (submitted).

An alternative approach to dose escalation to increase systemic 4-HPR levels is pharmacological modulation of 4-HPR metabolism. However, before mouse models can be used for pharmacokinetic studies of 4-HPR pharmacological modulation, differences in drug metabolism, if any, between humans and mice need to be defined. In rodents, 4-HPR is primarily metabolized to N-(4-methoxyphenyl)retinamide (4-MPR) (Hultin et al., 1986), whereas in humans, 4-HPR metabolism to 4-MPR and an additional metabolite, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), have been reported (Villani et al., 2004). 4-MPR is reported to be the most abundant metabolite of 4-HPR in both rodent and human plasma, with 4-oxo-4-HPR being present at lower concentrations in humans (Villani et al., 2004). 4-MPR is non-cytotoxic in numerous malignant cell lines, in vitro (Appierto et al., 2001; Mehta et al., 1998; Villani et al., 2006), while 4-oxo-4-HPR was 2- to 4-fold more cytotoxic than 4-HPR in solid tumor cell lines (Villani et al., 2006). While individual metabolites have been reported both in humans and rodent models, the metabolic pathways for 4-HPR in each species still remain poorly delineated.

Several cytochrome P450 (CYP) enzymes, including CYP3A4, 2C8, 2C9, and 26A1, are reported to metabolize all-trans retinoic acid (ATRA) into polar derivatives such as 4-oxo-RA (Thatcher, 2005), and these observations have been used to make predictions concerning metabolic pathways for 4-HPR. Villani et al. reported that CYP26A1 catalyzed the formation of 4-oxo-4-HPR from 4-HPR in a human ovarian carcinoma cell line, in vitro (Villani et al., 2004). Also, in mice pretreated with the CYP enzyme inducer phenobarbital prior to 4-HPR
administration, hepatic CYP enzyme levels were increased by three-fold and 4-HPR concentrations in plasma and tissues were decreased by 50% (Hultin et al., 1986). Triazole antifungal agents are known to inhibit members of the CYP family of enzymes and to both decrease the levels of polar metabolites of ATRA and prolong the biological half-life of ATRA (Van Wauwe et al., 1988; Van Wauwe et al., 1990). These observations suggest that inhibition of the mixed function oxidase system using triazoles could increase systemic 4-HPR levels. A similar approach employing concurrent ketoconazole, a triazole antifungal agent, was initially successful in increasing ATRA plasma levels for one or two days but failed to prevent the decrease of ATRA plasma levels at the end of a two-week treatment course, likely due to the inability of ketoconazole to adequately inhibit ATRA-induced CYP enzyme over the extended drugging period (Lee et al., 1995). However, unlike ATRA, where auto-induction of metabolism leads to a significant decrease in half-life and drug exposures during therapy (Muindi et al., 1994), 4-HPR exposures are relatively constant during treatment courses and do not show evidence of auto-induction of metabolism (Formelli and Cleris, 1993). Thus, in contrast to experiences with ATRA, we hypothesized that the use of triazoles to inhibit specific CYP enzymes that metabolize 4-HPR would increase systemic 4-HPR concentrations.

The purpose of this study was (1) to characterize and compare inter-species differences in the metabolism of 4-HPR in humans and mice, and (2) to determine whether pharmacological modulation of the metabolism of 4-HPR could result in higher 4-HPR plasma concentrations in mouse models. Our pharmacokinetic analyses of plasma from 4-HPR-treated patients and mice identified 6 common metabolites of 4-HPR in humans and mice. We also report in vitro and in vivo metabolism data suggesting that the inhibition of CYP3A4 using ketoconazole could result in higher systemic 4-HPR concentrations clinically.
MATERIALS AND METHODS

Chemicals

4-HPR, 4-MPR, and N-(4-ethoxyphenyl)retinamide (4-EPR) were supplied by the Developmental Therapeutics Program of the National Cancer Institute (NCI, Bethesda, MD). 4-oxo-4-HPR was synthesized as previously described (Villani et al., 2004). 4-HPR/LXS™ oral powder, and LXS™ oral powder is manufactured by Avanti Polar Lipids, Inc, Alabaster, AL under agreement with BioMolecular Products, Newburyport, MA, and the formulation was supported by NCI Rapid Access to Intervention Development Program. Ketoconazole, gemfibrozil, and fluconazole were from Sigma-Aldrich (St Louis, MO). Potassium phosphate monobasic, acetonitrile, methanol, and formic acid were from Fisher Scientific (Pittsburgh, PA).

Patients and Animals

Subjects whose plasma samples were analyzed for 4-HPR and metabolites were participating in a phase I trial for the treatment of relapsed and refractory high-risk neuroblastoma using 4-HPR delivered in an oral lipid matrix powder (4-HPR/LXS oral powder, 4-HPR/LXS). The study received Institutional Review Board approval, and all patients gave written informed consent. Trial design and interim results were reported (Marachelian et al., 2009). Briefly, the trial enrolled 30 evaluable patients to 8 dose levels (range 352 – 2210 mg·m⁻² per day 4-HPR). 4-HPR/LXS was administered twice daily for one week every 21 days. The 4-HPR plasma levels measured for three specific patients treated at the 595 mg·m⁻² per day dose level were chosen for this study. Patient and animal blood samples were collected in foil-wrapped heparinized tubes, centrifuged immediately, and plasma was retained and stored at -80 °C until analysis. All procedures were carried out in amber tubes and/or in the dark to prevent light exposure.
Five- to six-week old non-obese diabetic/severe combined immune deficiency (NOD/SCID) and athymic nude (nu/nu) mice were obtained from Charles River Laboratories International (Wilmington, MA). For each experiment, 4-HPR/LXS, 4-HPR/LXS + ketoconazole, or the LXS powder alone (negative control) was slurried in sterile water and administered via gavage. Exact dosing and number of doses before pharmacokinetic analysis are given in figure legends. All mice were housed, treated, and sacrificed according to protocols approved by the Institutional Animal Care and Use Committee.

**HPLC and Tandem Mass Spectrometry Analysis**

Levels of 4-HPR, 4-MPR, and 4-oxo-4-HPR were quantified using an HPLC assay (Vratilova et al., 2004) with the following modifications: HPLC was an Agilent 1200 system (Agilent Technologies, Palo Alto, CA); column was an Agilent Zorbax Eclipse reverse-phase C18 150 x 4.6 mm, 5 µm; gradient elution with 0.01 M ammonium acetate in water and methanol was used at 1 mL· min⁻¹; 4-oxo-4-HPR standard was added; calibration curve concentrations ranged 0.019 – 40.0 µg·mL⁻¹; injection volume into the HPLC was 30 µL; and 100 µL of each plasma sample was used for extraction and analysis. Data were acquired and integrated by ChemStation 3D software (Agilent).

Metabolites were identified using LC-tandem mass spectrometry (LC/MS/MS). An Agilent 1200 HPLC was used with an Applied Biosystems 4000 QTRAP MS/MS operated in electrospray positive ion mode. For sample preparation, 50 µL of plasma was fortified with internal standard (4-EPR) and 100 µL of acetonitrile was added, vortexed, and centrifuged at 9,300 RCF for 5 minutes. Ten µL of supernatant with adjusted composition was then injected into the LC/MS/MS. A Waters Corporation reverse-phase Symmetry C18 column 150 x 4.6 mm, 3.5 µm (Milford, MA) was used. Mobile phase consisted of acetonitrile and water with 0.1% formic acid and was delivered via gradient at 1.0 mL· min⁻¹. The system was operated in an information-dependent acquisition mode (threshold: 1000 cps), which was set to include an MS3
experiment following enhanced product ion spectrum for the parent ion in the transition. Ion source conditions were: curtain gas 25; collision gas Low; spray voltage 5000; temperature 700°C; source gas1 50; source gas2 50. Analyst (version 1.4.2) and LightSight Metabolite ID software (both Applied Biosystems) were used for data acquisition and processing.

**Human and Mouse Liver Microsomes**

4-HPR and 4-MPR metabolism assays were performed using 0.5 mg protein·mL⁻¹ of pooled human or pooled mouse liver microsomes, or human CYP3A4 isoenzyme microsomes (BD Biosciences). NADPH regenerating system consisted of solutions “A” and “B” (BD Gentest catalog no. 451220 and 451200). Inhibitors of CYP2C8 (gemfibrozil) (Scheen, 2007), CYP2C9 (fluconazole) (Nivoix et al., 2008), and CYP3A4 (ketoconazole) (Jia and Liu, 2007) were dissolved in methanol at stock concentrations up to 5 mM. Solutions “A” and “B”, liver microsomes, and inhibitors were combined in 0.1 M potassium phosphate buffer (pH 7.4), and incubated for 20 minutes at 37°C. Substrates were then added and the mixture was incubated while shaking in a 37°C water bath. When incubation times were completed, reactions were immediately terminated by addition of ice-cold acetonitrile fortified with internal standard (4-EPR), vortexed for 1 minute, and centrifuged at 2917 RCF for 10 minutes. Supernatants were collected and analyzed via HPLC as described above.

**Cell Lines**

Human acute lymphoblastic leukemia (ALL) cell lines COG-LL-317, -332, and -329 (all T-cell ALL); COG-LL-319 and -355 (both Pre-B ALL); and COG-LL-356 (Pro-B ALL); and neuroblastoma lines CHLA-90 and -136 were obtained from the Children’s Oncology Group Cell Culture Repository (www.COGcell.org). Cells were cultured in Iscove’s Modified Dulbecco’s Medium (Cambrex, Walkersville, MD) supplemented with 3 mM L-glutamine, 5 µg/mL insulin and 20% heat-inactivated fetal bovine serum (FBS). The human Pre-B ALL cell line NALM-6
(from Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany); and human cell lines CCRF-CEM, MOLT-3 and MOLT-4 (all T-cell ALL), RS4;11 (Pre-B ALL), GA-10 (B-cell Burkitt lymphoma), HuT-78 (cutaneous T-cell lymphoma), and Toledo (B-cell non-Hodgkin lymphoma), all from American Type Culture Collection, Manassas, VA, were maintained in RPMI-1640 (Mediatech Inc., Herdon, VA) supplemented with 10% heat-inactivated FBS. All lines tested mycoplasma-free. Lymphoid cell lines were maintained at 37°C in humidified incubators containing 5% O2, 5% CO2 and 90% N2, and neuroblastoma lines were maintained at 37°C in humidified incubators containing 95% room air and 5% CO2. Cell line identities were confirmed after each expansion but prior to freezing by short tandem repeat (STR) genotyping using Ampf/STR Identifier™ kit (Applied Biosystems) (Masters et al., 2001) and compared with the Children’s Oncology Group STR database (www.COGcell.org). STR profiles were performed in all cell lines for cell line identification one month before the experiments.

Real-Time RT-PCR

Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed using an Applied Biosystems Prism 7900HT system to quantify basal gene expression of CYP26A1 in each of fourteen malignant lymphoid cell lines and two neuroblastoma cell lines. The reagents, assay conditions, and data normalization methods were as previously described (Kang et al., 2008). Primers and probes for CYP26A1 (TaqMan Gene Expression Assay proprietary sequences, P/N 4331102; Applied Biosystems) were added according to the manufacturer’s instructions. Total RNA added per well was 300 ng for all cell lines except CCRF-CEM, for which 150 ng was added due to its apparent high level of CYP26A1 mRNA.
Statistical Analysis

Statistical evaluation was performed using Student’s $t$-test. $P$-values were two sided and tests were considered significant at $P < 0.05$. All in vitro experiments were performed in triplicate and were consistently repeatable; for simplicity, one representative experiment for each condition is shown.

RESULTS

Identification of 4-HPR Metabolites in the Plasma of 4-HPR-treated Patients and Mice

To identify metabolites of 4-HPR, we used LC/MS/MS to analyze plasma samples from 4-HPR-treated patients and mice. HPLC chromatograms of patient plasma and mouse plasma are shown in Figure 1A left and right panels, respectively. 4-HPR eluted at approximately 25.0 minutes and the detected metabolites had retention times ranging from 7.6 – 27.5 minutes. In both species, seven major peaks (peak area ratio > 0.04 relative to the parent drug in humans and > 0.12 relative to the parent drug in mice) representing different 4-HPR metabolites were detected, M1-M7 in mouse plasma and H2-H8 in human plasma. Six of these seven peaks, M2 – M7 in mouse plasma and H2 – H7 in human plasma, eluted at similar retention times (i.e., were “common” metabolites).

The results of MS/MS analysis of patient and mouse plasma are shown in Figure 1B. Two of the metabolites in patients (H6 and H7) and two in mice (M6 and M7) were detected using a positive precursor ion scan at m/z 283, which is the fragment occurring after loss of the amino-phenyl-hydroxy group. The structure of H7 and M7 identified the two metabolites as 4-MPR, while H6 and M6 showed an [M + H]$^+$ ion at m/z 568 and fragmentation spectra corresponding to the direct addition of glucuronide to 4-HPR. Metabolites H2 – H4, H8, and M2 – M4 were detected by a neutral loss scan of 109. The fragmentation spectra identified metabolites H4 and M4 as 4-oxo-4-HPR, and the spectra of H2, M2, and H8 each corresponded to a monohydroxy-4-oxo-4-HPR. The exact location of the hydroxyl group on the 4-oxo-
substituted β-ionone ring could not be determined for H2, M2, or H8 since hydroxylation could occur at any of the C-2, C-3, or C-18 positions. The metabolites H3 and M3 were identified as dehydrogenated 4-HPR. Finally, metabolites M1, H5, and M5 were detected by a precursor ion scan at m/z 313, which is the fragment occurring after loss of the amino-phenyl-hydroxy group from monohydroxy-4-oxo-4-HPR. Fragmentation spectra suggested that M1 was a glucuronidated metabolite and that H5 and M5 were both sulfated metabolites.

**In Vitro Metabolism of 4-HPR in Liver Microsomes and Malignant Mammalian Cells**

Identification of 4-oxo-4-HPR in the plasma of mice prompted us to measure and compare the Michaelis-Menten kinetic constants for the oxidation of 4-HPR to 4-oxo-4-HPR in pooled human liver microsomes (HLM) and pooled mouse liver microsomes (MLM) using HPLC (Figures 2A and B). The \( V_{\text{max}} \) was more than 3-fold greater for HLM compared with MLM (1.50 versus 0.42 nmol·hr\(^{-1}\) per mg protein), but the \( K_{\text{m}} \) values were equivalent (23.9 versus 25.8 \( \mu \)M), showing that 4-oxo-4-HPR generation in mice is slower but the total amount formed in mice is similar to humans. We also investigated whether 4-MPR, the major metabolite of 4-HPR, could be demethylated to form 4-HPR or 4-oxo-4-HPR in HLM (Figures 2C and D). Although the \( V_{\text{max}} \) and \( K_{\text{m}} \) values were low for 4-MPR, both 4-HPR and 4-oxo-4-HPR were detected as metabolites of 4-MPR in HLM. Neither 4-HPR nor 4-oxo-4-HPR were produced from 4-MPR at measurable concentrations in MLM (data not shown).

As the CYP enzymes 3A4, 2C8, 2C9, and 26A1 have been shown to metabolize ATRA into polar metabolites including 4-oxo-ATRA (Thatcher, 2005), we investigated whether these enzymes contributed to the formation of 4-oxo-4-HPR from 4-HPR in humans and mice. Three of these enzymes (CYP2C8, 2C9, and 3A4) are inhibited by agents that are readily available and well tolerated in humans, making the inhibitors of the enzymes clinically applicable for co-administration with 4-HPR. To identify the CYP enzymes mediating the conversion of 4-HPR to 4-oxo-4-HPR in HLM and MLM, inhibitors to CYP2C8 (gemfibrozil), 2C9 (fluconazole), and 3A4
(ketoconazole) were added to MLM and HLM in combination with 4-HPR and the amount of 4-oxo-4-HPR formation was measured via HPLC (Figure 3). A 4-HPR concentration of 25 μM, an approximated $K_m$ for both MLM and HLM experiment, was used for the formation of 4-oxo-4-HPR from 4-HPR. In MLM (Figure 3A), the addition of fluconazole reduced 4-oxo-4-HPR formation by 40.9% ± 4.1 at 10 μM from 4-HPR alone ($P < 0.01$) and ketoconazole reduced 4-oxo-4-HPR formation by 96.5% ± 3.1 at 10 μM from 4-HPR alone ($P < 0.001$). In HLM (Figure 3B), only ketoconazole reduced 4-oxo-4-HPR formation (33.7% ± 8.8 from 4-HPR alone at 10 μM, $P < 0.01$). To confirm that human CYP3A4 catalyzed the formation of 4-oxo-4-HPR from 4-HPR, we incubated 4-HPR (at 10 μM anticipating that the CYP3A4 isoenzyme activity would be higher than pooled human liver microsomes) in human CYP3A4 isoenzyme microsomes with the NADPH generating system and analyzed amounts of 4-HPR and 4-oxo-4-HPR via HPLC; 4-oxo-4-HPR concentrations in the CYP3A4 microsomes increased in a time-dependent manner (Figure 3C).

As ketoconazole at 10 μM partially inhibited 4-oxo-4-HPR production in HLM, and ketoconazole is reported to be specific for CYP3A4 at concentrations up to 1 μM but will inhibit other CYP isoforms at higher concentrations (Jia and Liu, 2007), we considered the possibility that other CYP enzymes might be contributing to 4-oxo-4-HPR formation in cancer patients. Expression of CYP26A1 was reported to be induced after exposure to 4-HPR in a human ovarian cancer cell line, and 4-oxo-4-HPR formation from 4-HPR was measured after overexpression of CYP26A1 (Villani et al., 2004), so we investigated whether CYP26A1 formed 4-oxo-4-HPR from 4-HPR in human malignant lymphoid cell lines and neuroblastoma cell lines. We first measured basal CYP26A1 mRNA levels via RT-PCR in fourteen malignant lymphoid cell lines grown at physiologic bone marrow level hypoxia (5% $O_2$) and two neuroblastoma cell lines grown at “normoxic” tissue culture conditions (20% $O_2$). 26A1 mRNA was quantified in all cell lines; the levels were comparable between the malignant lymphoid cells (range: 0.03 – 1.27)
and the neuroblastoma cells (CHLA-90: 0.108 and CHLA-136: 0.076). However, when we used HPLC to examine cellular extracts from five of the malignant lymphoid cell lines (CCRF-CEM, COG-LL-317, HuT-78, MOLT-3, and RS4;11) and both neuroblastoma cell lines after treatment with 2 – 10 µM 4-HPR for 12 and 24 hours, interestingly, 4-oxo-4-HPR was not formed at measurable concentrations (data not shown).

**Co-administration of Ketoconazole with 4-HPR Increased Systemic 4-HPR Levels In Vivo**

To examine whether the modulation of 4-HPR metabolism would alter systemic 4-HPR levels in vivo, we administered 4-HPR with or without ketoconazole at human treatment-equivalent dosing to nu/nu and NOD/SCID mice. In nu/nu mice (Figure 4A) the addition of 75 mg·kg⁻¹ of ketoconazole (representing a human equivalent dose of 6 mg·kg⁻¹, which is within the therapeutic dosing range for children and adults) increased 4-HPR plasma levels from 14.5 µM ± 4.7 to 31.5 µM ± 1.9 (a 2.2-fold increase over control, \( P < 0.01 \)), and in NOD/SCID mice (Figure 4B) ketoconazole significantly increased 4-HPR plasma levels at all doses (at 18.75 mg·kg⁻¹, an increase from 8.5 µM ± 4.4 to 28.9 µM ± 3.1, a 3.4-fold increase over control, \( P < 0.01 \)). In a separate experiment, the addition of 25 mg·kg⁻¹ ketoconazole to 4-HPR in NOD/SCID mice (Figure 4C) increased 4-HPR plasma levels from 15.6 µM ± 4.5 to 31.6 µM ± 2.7 (a 2.0-fold increase over control, \( P < 0.02 \)) and also increased levels of 4-oxo-4-HPR from 3.6 µM ± 0.4 to 7.2 µM ± 0.8 (a 2.0-fold increase over control, \( P < 0.01 \)).

**Comparison of Levels of 4-HPR and Its Metabolites in the Plasma of 4-HPR-treated Patients and Mice**

Using HPLC, we analyzed the concentrations of 4-HPR, 4-MPR, and 4-oxo-4-HPR in the plasma of three patients enrolled in a phase I clinical trial of 4-HPR/LXS (Table 1). The plasma of the three patients treated at the 4-HPR dose-level of 595 mg·m⁻² per day was sampled at up to 8 hours after treatment on Day 6 of Cycle 1. In patient plasma 4 hours after treatment (the
middle of the 8-hour sampling period), 4-HPR, 4-MPR, and 4-oxo-4-HPR levels were 12.82 µM ± 8.08, 5.72 µM ± 4.21, and 0.86 µM ± 0.66, respectively. By comparison, in the plasma of NOD/SCID mice that were administered 4-HPR/LXS at a 4-HPR dose approximately equivalent to the dose administered in the patients (patients: 595 mg·m⁻² per day and mice: 180 mg·kg⁻¹ per day) (Reagan-Shaw et al., 2008), average levels of 4-HPR, 4-MPR, and 4-oxo-4-HPR were 15.6 µM ± 4.5, 1.6 µM ± 0.2, and 3.6 µM ± 0.4, respectively (control mice in Figure 4C).

DISCUSSIONS AND CONCLUSIONS

Low plasma drug levels and tumor response rates in clinical trials employing an oral corn-oil slurry based 4-HPR capsule have led investigators to suggest that higher systemic 4-HPR exposures may be required for improving clinical outcomes (Cheng et al., 2001; Puduvalli et al., 2004; Reynolds et al., 2007; Vaishampayan et al., 2005; William, Jr. et al., 2009). As a result, new formulations that increase 4-HPR bioavailability have been developed (Liu et al., 2007; Maurer et al., 2007) and are currently being tested in phase I trials (Marachelian et al., 2009; Mohrbacher et al., 2007). However, the possibility that systemic 4-HPR exposures could be further improved by modulating 4-HPR metabolism in conjunction with oral delivery has not been investigated. Based on reports suggesting that both ATRA and 4-HPR metabolism occurs via CYP enzymes (Hultin et al., 1986; Thatcher, 2005; Van Wauwe et al., 1988; Van Wauwe et al., 1990; Van et al., 1994; Villani et al., 2004), we hypothesized that pharmacologic inhibition of CYP enzymes that metabolize 4-HPR using clinically-available agents might increase systemic 4-HPR concentrations. Therefore, to explore this hypothesis, we first investigated how 4-HPR metabolism in humans compared with in vivo murine models as the metabolic pathways for 4-HPR are poorly defined in both species. In this study, we determined both similarities and differences in 4-HPR metabolism between humans and mice; using human and mouse liver microsomes we demonstrated that 4-oxo-4-HPR is formed from 4-HPR by CYP3A4 in mice and, in part, by CYP3A4 in human cells in vitro; we further demonstrated that the co-administration of
the CYP3A4-inhibitor, ketoconazole, with 4-HPR in vivo increased 4-HPR plasma concentrations in mice.

The demonstrated similarities and differences in 4-HPR metabolism between humans and mice suggests that mouse models may be useful in vivo models of 4-HPR pharmacokinetics and studies of pharmacologic manipulation in humans within certain limitations. Specifically, differences in the kinetic constants for oxidation of 4-HPR to 4-oxo-4-HPR in HLM and MLM were observed, suggesting that mice proportionately oxidize a greater portion of 4-HPR to 4-oxo-4-HPR than do humans. Also, the observation that ketoconazole inhibited 4-HPR conversion to 4-oxo-4-HPR at lower concentrations in MLM than in HLM, suggesting that mice may rely more heavily on CYP3A4 for 4-oxo-4-HPR formation than humans. In terms of similarities, the low kinetic constants for conversion of 4-MPR to 4-HPR or 4-oxo-4-HPR in HLM (Figures 2C and D) and the absence of conversion in MLM suggest that neither conversion occurs at high rates or amounts in humans or mice. Thus, while 4-MPR is reported to accumulate to high levels in plasma and tissues and to have a longer half-life than 4-HPR (Formelli and Cleris, 1993; Formelli et al., 2008; Sabichi et al., 2003), it is unlikely that back conversion (i.e., “recycling”) of the 4-MPR pool in plasma significantly contributes to systemic 4-HPR levels or tumor cell 4-HPR exposure. A proposed biotransformation pathway of 4-HPR is shown in Figure 5 based on the data from human and mouse plasma analyses and the in vitro enzyme kinetic studies.

Our in vitro studies demonstrated that inhibitors of both CYP2C9 (fluconazole) and CYP3A4 (ketoconazole) significantly reduce 4-oxo-4-HPR formation in MLM, but that in HLM ketoconazole only partially reduced 4-oxo-4-HPR formation. We then demonstrated that the co-administration of ketoconazole at human treatment-equivalent doses with 4-HPR in vivo increased 4-HPR plasma levels by at least 2-fold in two strains of mice, with NOD/SCID mice possibly being more sensitive to ketoconazole effects than nu/nu mice. These in vitro and in vivo data are compatible with results from a study by Illingworth (Illingworth et al., 2010), and
support the role of CYP3A4 in the oxidation of 4-HPR. However, given that relatively high concentrations of ketoconazole were used to inhibit 4-oxo-4-HPR formation in HLM both in our study (10 μM) and in the study by Illingworth et al., (100 μM), it is likely that other CYP enzymes in addition to 3A4 contribute to 4-oxo-4-HPR formation in humans.

Based on the fact that we observed greater inhibition of 4-oxo-4-HPR formation by ketoconazole in MLM versus HLM (96.5% versus 33.7% at 10 μM, see Figures 3A and B), the present results suggest that murine experiments may over-estimate the increase in 4-HPR plasma levels to be expected in humans when using concurrent administration of ketoconazole and 4-HPR if such increases are based solely on the inhibition of metabolism of 4-HPR to 4-oxo-4-HPR. Further, we recognize that ketoconazole may inhibit other CYP enzyme isoforms in addition to 3A4 at concentrations above 1 μM (Jia and Liu, 2007). Thus ketoconazole co-treatment has the potential to decrease the conversion of 4-HPR to metabolites other than 4-oxo-4-HPR and could result in higher 4-HPR plasma levels in patients than would be suggested by analysis of 4-oxo-4-HPR formation alone in HLM. Also, importantly, although 4-oxo-4-HPR may obtain lower steady-state plasma levels than other 4-HPR metabolites in humans, the specific mass per time (flux) of 4-HPR through 4-oxo-4-HPR metabolism in humans is not known and, if great enough, could represent a useful target for pharmacologic intervention by ketoconazole or other agents on this basis.

Based on microsomal results, in addition to increasing 4-HPR plasma levels we expected that co-administration of ketoconazole to mice would also result in a concomitant rise in 4-MPR plasma levels (as oxidation of 4-HPR was inhibited, more 4-HPR was available to the other metabolic pathways). However, in addition to a slight increase in 4-MPR levels, surprisingly, ketoconazole increased 4-oxo-4-HPR plasma levels in mice (Figure 4C), perhaps a counterintuitive result. Considering that CYP3A4 may also mediate the formation of dehydrogenated 4-HPR and hydroxy-4-oxo-4-HPR, and that the metabolism of both ATRA and
4-oxo-4-ATRA has been reported to be inhibited by imidazole-containing P450 inhibitors such as ketoconazole and liarazole (Chithalen et al., 2002; Hultin et al., 1986; Van Wauwe et al., 1990; Van et al., 1994), it is possible that other CYP enzymes, including CYP26A1 whose expression has been shown to be inducible by ATRA and 4-HPR (Ozpolat et al., 2002; Ozpolat et al., 2004; Sonneveld et al., 1998; Villani et al., 2004), may also contribute to the in vivo formation of 4-oxo-4-HPR. Another possible explanation of having slightly increased 4-oxo-4-HPR in mice is that ketoconazole inhibited further degradation of 4-oxo-4-HPR into hydroxyl-4-oxo-4-HPR (see Fig. 5), and that the increases in 4-HPR concentration resulted from the inhibition of dehydrogenated 4-HPR formation which generated more 4-oxo-4-HPR in sequence.

Since the metabolite 4-oxo-4-HPR is reported to exhibit more potent anti-tumor activity than 4-HPR and has also been shown to act synergistically with the parent compound (Villani et al., 2006), one may question whether the inhibition of 4-oxo-4-HPR formation might compromise the efficacy of 4-HPR. While the anti-tumor activity of 4-HPR has been demonstrated both in in vivo models and clinically (Marachelian et al., 2009; Maurer et al., 2007; Mohrbacher et al., 2007; Reynolds et al., 2007), only in vitro studies with 4-oxo-4-HPR are reported and it has not been investigated whether this translates to an anti-tumor role in vivo. Further, it is hypothesized that sufficiently increasing 4-HPR levels will result in increased anti-tumor activity that will more than adequately compensate for a possible partial decrease in 4-oxo-4-HPR levels. Indeed, in our in vivo mouse experiments, ketoconazole did not appreciably reduce 4-oxo-4-HPR levels in the plasma while 4-HPR concentrations approximately doubled, suggesting the further metabolism of 4-oxo-4-HPR to hydroxy-4-oxo-4-HPR might have been inhibited by ketoconazole as previously discussed.

Unfortunately, due to the lack of a sufficiently specific inhibitor of CYP26A1 and CYP26A1 isoenzymes, we could not address whether the formation of 4-oxo-4-HPR from 4-HPR is also catalyzed by CYP26A1 using liver microsome analyses or in vivo mouse studies. However, we assayed 4-oxo-4-HPR formation in seven human malignant lymphoid and
neuroblastoma cell lines expressing CYP26A1 that were exposed to 4-HPR and 4-oxo-4-HPR was not measurable in any of the cell lines tested. These results in lymphoid cancer and neuroblastoma cell lines with basal levels of CYP26A1 expression differ from those reported by Villani et al., who employed forced overexpression of CYP26A1 in an ovarian cancer cell line (Villani et al., 2004), and may have therapeutic implications. Our results suggest that the limited amount of internal tumor 4-oxo-4-HPR formed by CYP26A1 and/or other enzymes in human malignant lymphoid and neuroblastoma cell types in vivo may not be responsible for the observed 4-HPR clinical activity, although our studies did not address the possible effects of peripheral tissue metabolism of 4-HPR to 4-oxo-4-HPR and the effects of those 4-oxo-4-HPR sources on tumor responses. Conceivably, 4-HPR-resistant malignant cells may have increased expression of CYP26A1 and be capable of generating clinically significant local amounts of 4-oxo-4-HPR. Thus, it is difficult to directly predict the clinical impact, if any, that 4-HPR-resistant, 4-oxo-4-HPR-producing malignant cells may have on 4-HPR global pharmacokinetics as the relative contributions to 4-HPR metabolism of various tissues (liver, intestines, kidneys, etc.) and of varying tumor cell burdens remain to be determined.

Finally, we compared the levels of 4-HPR, 4-MPR, and 4-oxo-4-HPR in the plasma of 4-HPR-treated patients and mice treated with human-equivalent doses of 4-HPR (Reagan-Shaw et al., 2008). When compared to 4-HPR and metabolite plasma concentrations observed in a phase I trial employing oral capsule 4-HPR in pediatric neuroblastoma patients at similar doses, the 4-HPR and 4-MPR levels measured in patients treated with 4-HPR/LXS poral powder appeared to be higher but the 4-oxo-4-HPR levels were approximately equivalent. Further, while the 4-HPR plasma concentrations measured in the present investigation were not appreciably different between patients and mice dosed on an equivalent basis, NOD/SCID mice appeared to convert more 4-HPR to 4-oxo-4-HPR while humans preferentially metabolized 4-HPR to 4-MPR (Table 1 and control mice in Figure 4C). This observed result seems to be at odds with the kinetic constants estimated by our in vitro studies, which suggested that humans and mice
would form similar amounts of 4-oxo-4-HPR. Kinetic data, however, cannot be interpreted in isolation as other reactions which may influence drug metabolism. It is also worth noting that our clinical and in vivo data are currently limited by small numbers of patients, a restricted patient age range (< 26 years old), and by the number of strains of mice analyzed for 4-oxo-4-HPR. Further, the potentially greater responsiveness of NOD/SCID mice with respect to the extent to which ketoconazole increased 4-HPR levels (Figures 4A and 4B) suggests that not all mouse strains metabolize 4-HPR equivalently.

In summary, our evidence suggests that, overall, humans and mice metabolize 4-HPR to a common set of metabolites and the demonstration that co-administration of ketoconazole increased systemic 4-HPR levels in mice strongly support the possibility that a similar effect may be observed in patients. The addition of a study arm to test the effect of co-administration of ketoconazole on 4-HPR plasma levels and systemic toxicity in an ongoing phase I trial of 4-HPR/LXS oral powder in pediatric neuroblastoma in the New Approaches to Neuroblastoma Therapy (NANT) Consortium (www.NANT.org, Study number: N2004-04) is in progress. Considering that relatively low human-equivalent doses of ketoconazole were sufficient to increase 4-HPR systemic exposure in mice, the combination of 4-HPR and ketoconazole is expected to be well tolerated in patients.
Acknowledgements: This work was funded by grants from the Cancer Prevention and Research Institute of Texas (CPRIT: RP10072), and National Institutes of Health (CA82830, CA100895, CA81403, CA49837); and by The AT&T Foundation. The authors would like to acknowledge The New Approaches to Neuroblastoma Therapy (www.NANT.org) Consortium and The Children’s Neuroblastoma Cancer Foundation (www.CNCFhope.org) for providing patient samples for the study.
References


O'Donnell PH, Guo WX, Reynolds CP & Maurer BJ. (2002). N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. *Leukemia*, 16: 902-910.


Reynolds CP, Frigala T, Tsao-Wei D, Groshen S, morgan R, McNamara M, Scudder S, Zwiebel JA, Lenz HJ & Garcia AA. (2007). High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: A study by the California Cancer Consortium. p. 5555.


Table 1. 4-HPR, 4-MPR, and 4-oxo-4-HPR levels in plasma of neuroblastoma patients

<table>
<thead>
<tr>
<th>Hours after last treatment</th>
<th>Mean ± SD (µM)</th>
<th>4-HPR</th>
<th>4-MPR</th>
<th>4-oxo-4-HPR††</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n = 3)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>7.04 ± 4.75</td>
<td>4.03 ± 2.98</td>
<td>0.91‡</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>9.69 ± 7.30</td>
<td>4.91 ± 3.69</td>
<td>1.27‡</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>12.82 ± 8.08</td>
<td>5.72 ± 4.21</td>
<td>0.86 ± 0.66§</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>13.11 ± 8.50</td>
<td>6.61 ± 5.75</td>
<td>0.43‡</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>8.55 ± 6.42</td>
<td>4.69 ± 3.92</td>
<td>1.00 ± 0.72</td>
<td></td>
</tr>
</tbody>
</table>

† n = 3 patients treated at the 595 mg·m⁻² per day dose level. All plasma samples collected on Day 6 of Cycle 1.

†† Not all patients were analyzed for 4-oxo-4-HPR at the indicated hour: ‡ n = 1, § n = 2, || n = 3
FIGURE LEGENDS

Figure 1. Identification of 4-HPR metabolites in plasma of 4-HPR-treated patients and mice. 
(A) HPLC chromatograms showing metabolite peaks in humans (H2 – H8, left) and mice (M1 – M7, right). Pre 4-HPR (blue), After 4-HPR (red). (B) Structural identification of H2 – H8 and M1 – M7 via MS/MS. Dehydration that occurred during fragmentation of M1, H2/M2, H5/M5, and H8 would likely involve the hydroxyl (-OH) group highlighted with red box.

Figure 2. In vitro metabolism of 4-HPR and 4-MPR in pooled human (HLM) and mouse liver microsomes (MLM). (A) Rate of 4-oxo-4-HPR formation from 4-HPR in HLM and (B) in MLM. (C) Rate of demethylation of 4-MPR to the parent drug in HLM. (D) Rate of 4-oxo-4-HPR formation from 4-MPR in MLM. For A – D, substrates at indicated concentrations were incubated in HLM or MLM for 60 minutes. Points in each graph are the mean and error bars are standard deviation from experiments performed in triplicate. Amounts measured by HPLC were normalized to the amount of HLM or MLM protein. In each graph, the $K_m$ (µM) and $V_{max}$ (nmol·hr$^{-1}$ per mg protein) are the mean ± SD.

Figure 3. CYP enzymes catalyzing the formation of 4-oxo-4-HPR from 4-HPR. (A, B) Analysis of the effects of CYP enzyme inhibitors on 4-oxo-4-HPR formation from 4-HPR in (A) pooled mouse (MLM) and (B) pooled human liver microsomes (HLM). 4-HPR (25 µM) was incubated with or without the indicated concentration of CYP enzyme inhibitor in MLM or HLM for 60 minutes before analysis via HPLC. (C) Formation of 4-oxo-4-HPR (■) from 4-HPR (□) via human CYP3A4 isoenzyme. In human CYP3A4 isoenzyme microsomes, 4-HPR (10 µM) was incubated for the times indicated. Amounts of 4-HPR and 4-oxo-4-HPR measured by HPLC were normalized to the amount of CYP3A4 protein. 4-HPR (10 µM) was used as a positive control in HLM to confirm the generation of 4-oxo-4-HPR. For A-C the points/columns are the mean and...
Figure 4. Co-administration of ketoconazole increased systemic 4-HPR levels in mice in vivo. (A) 4-HPR (■) and 4-MPR (□) levels in plasma of nu/nu mice administered 4-HPR with increasing doses of ketoconazole. Control mice were sacrificed four hours after the fifth dose and other groups were sacrificed four hours after the ninth dose. (B) 4-HPR (■) and 4-MPR (□) levels in plasma of NOD/SCID mice administered 4-HPR with increasing doses of ketoconazole. Sacrifice times were the same as described for Figure 4A. (C) 4-HPR (■), 4-MPR (□), and 4-oxo-4-HPR (■) levels in plasma of NOD/SCID mice administered 4-HPR alone or with ketoconazole (25 mg·kg⁻¹). Mice in both groups were sacrificed four hours after the fifth dose. In panels A – C, all mice received 4-HPR (180 mg·kg⁻¹ per day) gavaged in two divided doses; control mice for all experiments received 4-HPR without ketoconazole. Cohorts of three mice were used for each condition and columns are the mean and error/vertical bars are standard deviation from experiments performed in triplicate. * P < 0.02, ** P < 0.01.

Figure 5. Proposed phase I and II biotransformation pathway for 4-HPR. Potential pathways for the interconversion of one metabolite into another, i.e. the conversion of 4-MPR to 4-oxo-4-HPR, have been omitted due to the very low/no conversion kinetic parameters observed in HLM and MLM.
**Statement of conflict of interest:** Certain intellectual property rights to 4-HPR/LXS™ oral powder, intravenous fenretinide emulsion and fenretinide in combination with ketoconazole, as cited here may be retained by The Childrens Hospital Los Angeles. BJM and CPR are co-inventors of this intellectual property and may potentially benefit financially from said intellectual property.
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.